PharmTech Drug Digest 11.20
News|Articles|October 3, 2014

Milan API Producer Opens High-Potent API Plant

LABOCHIM SpA completes construction on multipurpose high-potent API plant in Milan.

INFA GROUP SpA, an API producer in Milan, announced on Sept. 29, 2014 that its Segrate Milan manufacturing subsidiary, LABOCHIM SpA, has completed construction on a new multipurpose high-potent API plant. The new laboratory has a capacity of up to 2.5 Kg/batch size and manufacturing capabilities ranging from 100 grams to tens of kilograms of both advanced intermediates and APIs, classified from OEB3 to OEB5.

The company believes the new plant will expand INFA’s portfolio of products and services for both the generic-drug and CDMO segments. This plant offers INFA’s customers unique flexibility and will be exclusively dedicated to therapeutic areas outside of oncology.

Source: INFA GROUP SpA

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.